Purchase Link:
http://www.research-store.com/fiercebiotech/Product/the_gastrointestinal_market_outlook_to_2014_market_dynamics_competitive_landscape_emerging_therapies?productid=FAEB268F-5F91-4502-95CE-F7500DA6D40B
Introduction
The gastrointestinal market is mature and genericized. Over 2004-08, most of the market leading drug classes in this therapy area reported negative or low compound annual growth rates (CAGRs). The largest drug class of the therapy area, proton pump inhibitors, which constituted a market share of 53.2%, recorded a CAGR of 4.8%.
Scope of this research
- Epidemiological analysis of the therapy area and forecast prevalence over 2009-14.
- Forecasts and analysis of the key products in the gastrointestinal market over 2009-14 across major classes of treatments.
- Overview of key events in the global gastrointestinal market that have impacted treatment trends and sales potential.
- Strategic and growth analysis of leading pharmaceutical corporations.
- Detailed analysis across major classes of gastrointestinal treatment, including immunosuppressants and anti-rheumatic agents.
Research and analysis highlights
Growth in the Crohn's disease and ulcerative colitis market is likely to be driven by self-injectable products. This would lead to the transition of a significant proportion of patients on Remicade therapy to these products. The convenience of self-injection would help in driving growth in this category while facilitating earlier use of drugs.
Adolor and GSK's mu-opioid receptor antagonist, Entereg (alvimopan), which was being studied in opioid bowel dysfunction (OBD) treatment, was suspended from further development by the companies based on their assessment of the timeline and cost of another Phase III trial, in relation to its remaining commercial life.
Many of the top 10 players posted a decline in sales over 2007, a fact indicative of the high degree of genericization in the market. Overall, drugs indicated for the treatment of ulcer are expected to drag down the sales of most players.
Key reasons to purchase this research
- Develop insights into patient potential with the report's coverage of the therapy area and top 10 leading gastrointestinal players today.
- Quickly understand how recent events are affecting the performance of major products and how leading players are confronting competitive challenges.
- Gain up-to-date market intelligence across the gastrointestinal category and understand the major issues affecting key pharmaceutical marketers.
- Understand which drug classes have the greatest potential to drive gastrointestinal franchise growth.
- Compare the franchises of leading pharmaceutical companies across key therapeutic classes.
Teaser:
The gastrointestinal market is mature and genericized. Over 2004-08, most of the market leading drug classes in this therapy area reported negative or low compound annual growth rates (CAGRs). The largest drug class of the therapy area, proton pump inhibitors, which constituted a market share of 53.2%, recorded a CAGR of 4.8%.
